Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15298854 | 1.00 | MAPT (0.44) | MAPTHDAC8KMT2AGAACYP3A4 | |
| SCHEMBL15976393 | 0.80 | MEN1 (0.34) | MAPTKMT2AGAAMEN1 | |
| SCHEMBL12020037 | 0.80 | MEN1 (0.34) | MAPTKMT2AGAAMEN1 | |
| SCHEMBL7662496 | 0.78 | SMN1; SMN2 (0.34) | MAPTKMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL7659302 | 0.74 | ALDH1A1 (0.40) | MAPTKMT2ACYP1A2KDM4EALDH1A1 | |
| SCHEMBL16117006 | 0.73 | — | — | |
| SCHEMBL11957430 | 0.73 | — | — | |
| SCHEMBL5283640 | 0.73 | CYP1A2 (0.36) | MAPTKMT2ACYP1A2KDM4EALDH1A1 | |
| SCHEMBL24608268 | 0.73 | HDAC8 (0.53) | MAPTHDAC8KMT2AGAACYP3A4 | |
| SCHEMBL762450 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028255-A1 | POLY(AMINO ACID) BASED CAPSULES | AGFA-GEVAERT NV (BE) | 2024-02-08 | — | — | WO | disclosed |
| WO-2022194759-A1 | POLY(AMINO ACID) BASED CAPSULES | AGFA-GEVAERT NV (BE) | 2022-09-22 | — | — | WO | disclosed |
| US-20220144760-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | FUJIFILM CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220135517-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | FUJIFILM CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2021033505-A1 | METHOD FOR PRODUCING CARBONYL COMPOUND AND FLOW REACTION SYSTEM USED FOR PRODUCTION OF CARBONYL COMPOUND | 富士フイルム株式会社 | 2021-02-25 | — | — | WO | disclosed |
| WO-2021033504-A1 | METHOD FOR PRODUCING CARBONYL COMPOUND AND FLOW REACTION SYSTEM USED FOR PRODUCTION OF CARBONYL COMPOUND | 富士フイルム株式会社 | 2021-02-25 | — | — | WO | disclosed |
| EP-2035442-B1 | NEW SUPPORTED OXIDATION REACTANTS, PROCESS FOR THEIR PREPARATION AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2011-10-12 | — | — | EP | disclosed |
| US-20110003943-A1 | Supported Oxidation Reactants, Process for their Preparation and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-01-06 | — | — | US | disclosed |
| US-20110003943-A1 | Supported Oxidation Reactants, Process for their Preparation and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-01-06 | — | — | US | disclosed |
| WO-2007144411-A1 | NEW SUPPORTED OXIDATION REACTANTS, PROCESS FOR THEIR PREPARATION AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003943-A1 | Supported Oxidation Reactants, Process for their Preparation and Uses Thereof | DAO, MTR, MET | MAPT 4100/4885HDAC8 4868/4885KMT2A 1336/4885 |
| US-20220135517-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | PARG, PTGIS, MT-ATP8 | MAPT 2131/4885HDAC8 4258/4885KMT2A 3614/4885 |
| US-20220144760-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | NOXO1, MT-CO2, MT-ATP8 | MAPT 2763/4885HDAC8 3359/4885KMT2A 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.